IMS Health Announces Expiration of Consent Solicitation, Receipt of the Requisite Consents and Execution of the Supplement

NORWALK, Conn.--(BUSINESS WIRE)-- IMS Health Incorporated announced that the consent solicitation with respect to its outstanding 12½% senior notes due 2018 has expired as of 5:00 p.m., ET, today and that it has received consents from noteholders representing in excess of a majority in aggregate principal amount of its outstanding Notes. Following receipt of the consents described above, the Company and certain of its subsidiaries executed a supplemental indenture providing for the amendments described in the Consent Solicitation Statement dated March 3, 2011 and the related consent letter. The amendments are operative with respect to all noteholders, including those noteholders who did not consent to the amendments.

Noteholders that have validly delivered, and not properly revoked, a consent to the proposed amendments may no longer revoke such consent. According to US Bank National Association, the Information and Tabulation Agent, consents have been received with respect to a majority of the aggregate principal amount of the outstanding Notes.

This announcement is not an offer to purchase or sell, a solicitation of an offer to purchase or sell, or a solicitation of consents with respect to any securities. The solicitation is being made solely pursuant to the Consent Solicitation Statement and the related consent letter.

About IMS Health

IMS Health is the leading provider of information services for the healthcare industry around the world. The Company draws on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and consulting platforms to help clients better understand the performance and value of medicines. With a presence in 100+ countries and more than 55 years of industry experience, IMS Health serves leading decision makers in healthcare, including pharmaceutical manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. Additional information is available at

This press release contains and incorporates by reference statements that, in our opinion, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “foresee,” “likely,” “project,” “estimate,” “will,” “may,” “should,” “future,” “predicts,” “potential,” “continue” and similar expressions identify these forward-looking statements, which appear in a number of places in this press release and the documents referred to herein and include, but are not limited to, all statements relating directly or indirectly to, plans for future growth, including our proposed acquisition of SDI Health LLC, and other business development activities as well as the proposed amendment of our senior secured credit facilities, capital expenditures, financing sources, dividends and the effects of regulation and competition, foreign currency conversion and all other statements regarding our intent, plans, beliefs or expectations or those of our directors or officers. Holders are cautioned that such forward-looking statements are not assurances for future performance or events and involve risks and uncertainties that could cause actual results and developments to differ materially from those covered in such forward-looking statements.

All forward-looking statements included in this press release and the documents referred to herein are based on information available to the Company on the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements contained throughout this press release and the documents referred to herein.


IMS Health Incorporated
Tammy Tobin, 203-845-5247
Investor Relations
[email protected]

KEYWORDS:   United States  North America  Connecticut

INDUSTRY KEYWORDS:   Technology  Data Management  Health  General Health


Suggested Articles

Here's how the COVID-19 pandemic changed healthcare executives' focus on technology and what to expect in 2021.

Cigna subsidiary Evernorth is launching FamilyPath, an integrated solution aimed at helping users navigate their fertility journey.

One of the largest pharmaceutical companies in the world is testing the delivery of vaccines via drone to get them to patients faster.